251 related articles for article (PubMed ID: 29280483)
21. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
22. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
[TBL] [Abstract][Full Text] [Related]
23. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Lundh H; Nilsson O; Rosén I; Johansson S
Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
[TBL] [Abstract][Full Text] [Related]
24. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
McEvoy KM; Windebank AJ; Daube JR; Low PA
N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
[TBL] [Abstract][Full Text] [Related]
25. Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Satoh K; Motomura M; Suzu H; Nakao Y; Fujimoto T; Fukuda T; Nakane S; Nakamura T; Eguchi K
J Neurol Sci; 2001 Jan; 183(1):1-4. PubMed ID: 11166786
[TBL] [Abstract][Full Text] [Related]
26. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
27. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
28. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.
Lindquist S; Stangel M
Neuropsychiatr Dis Treat; 2011; 7():341-9. PubMed ID: 21822385
[TBL] [Abstract][Full Text] [Related]
29. Neuromuscular junction disorders beyond myasthenia gravis.
Oh SJ
Curr Opin Neurol; 2021 Oct; 34(5):648-657. PubMed ID: 34914667
[TBL] [Abstract][Full Text] [Related]
30. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Lee MK; Sunwoo IN; Kim SM
J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
[TBL] [Abstract][Full Text] [Related]
31. Myasthenia gravis Lambert-Eaton overlap syndrome.
Oh SJ
Muscle Nerve; 2016 Jan; 53(1):20-6. PubMed ID: 26418033
[TBL] [Abstract][Full Text] [Related]
32. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Schneider I; Kornhuber ME; Hanisch F
J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
[TBL] [Abstract][Full Text] [Related]
33. [Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
Matsushima M; Yaguchi H; Kishimoto R; Tsuji S; Yabe I; Sasaki H; Nakadate M; Shiraishi H; Motomura M
Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1709-11. PubMed ID: 17802724
[No Abstract] [Full Text] [Related]
34. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Chan KY; Chang RS; Lau VW; Chan ML; Lai T
Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
[TBL] [Abstract][Full Text] [Related]
35. Treatment in Lambert-Eaton myasthenic syndrome.
Maddison P
Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581
[TBL] [Abstract][Full Text] [Related]
36. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
37. [A retrospective study of the effects of 3,4-diaminopyridine treatment in Lambert-Eaton myasthenic syndrome].
Naganuma R; Yabe I; Takahashi I; Matsushima M; Kano T; Sasaki H
Rinsho Shinkeigaku; 2018 Feb; 58(2):83-87. PubMed ID: 29386498
[TBL] [Abstract][Full Text] [Related]
38. Single-fiber EMG with concentric electrodes in lambert-eaton myasthenia.
Guan Y; Ding Q; Liu M; Niu J; Cui L
Muscle Nerve; 2017 Aug; 56(2):253-257. PubMed ID: 27935068
[TBL] [Abstract][Full Text] [Related]
39. [Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
Jost WH; Mielke U; Forrett-Kaminsky MC; Schimrigk K
Rev Neurol (Paris); 1992; 148(12):776-9. PubMed ID: 1303573
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up in infantile-onset lambert-eaton myasthenic syndrome.
Portaro S; Parisi D; Polizzi A; Ruggieri M; Andreetta F; Bernasconi P; Toscano A; Rodolico C
J Child Neurol; 2014 Sep; 29(9):NP58-61. PubMed ID: 24114606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
